Literature DB >> 14750539

Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population.

Rebecca A Harris1, Gang Chen, Wen Yao Lin, Fu Min Shen, W Thomas London, Alison A Evans.   

Abstract

Chronic hepatitis B virus (HBV) carriers with high-titer viremia (>10(5) virions/ml) are at increased risk for hepatocellular carcinoma (HCC). The aim of this study was to determine the relationship between clearance of high-titer viremia and subsequent risk of HCC. The study population was a prospective cohort of 114 adults from Haimen City, China, all HBV DNA(+) at study entry and followed for 797.8 person-years in total. During follow-up, 54 (47.4%) subjects spontaneously cleared high-titer viremia at least once. Of these, 27 were considered to have undergone stable seroconversion, 16 were considered unstable (12 reversions to HBV DNA positivity and 4 multiple clearances), and 11 did not have sufficient follow-up to determine stability. Of the 114 persons, 26 (22.8%) died during follow-up, 21 (18.4%) from HCC. Using Cox proportional hazards models, the RR of HCC death associated with seroconversion was 2.8 (95% CI = 1.1-7.4), controlling for age, sex, family HCC history, history of acute hepatitis, alcohol use and cigarette smoking. In conclusion, fluctuations of high-titer viremia may indicate increased hepatocellular damage and at least short-term increases in HCC risk. Long-term longitudinal studies are needed to clarify this relationship and its potential usefulness as a prognostic marker in chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14750539     DOI: 10.1023/b:caco.0000007984.79987.ec

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  6 in total

Review 1.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

2.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

3.  High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study.

Authors:  Jin-Yong Zhou; Le Zhang; Lei Li; Guang-Yu Gu; Yi-Hua Zhou; Jun-Hao Chen
Journal:  Virol J       Date:  2012-01-13       Impact factor: 4.099

4.  Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study.

Authors:  Oh Sang Kwon; Young Kul Jung; Yun Soo Kim; Sang Gyune Kim; Young Seok Kim; Jung Il Lee; Jin Woo Lee; Young Soo Kim; Byung Chul Chun; Ju Hyun Kim
Journal:  Korean J Hepatol       Date:  2010-09

5.  Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients.

Authors:  Tomoo Miyauchi; Tatsuo Kanda; Masami Shinozaki; Hidehiro Kamezaki; Shuang Wu; Shingo Nakamoto; Kazuki Kato; Makoto Arai; Shigeru Mikami; Nobuyuki Sugiura; Michio Kimura; Nobuaki Goto; Fumio Imazeki; Osamu Yokosuka
Journal:  Int J Med Sci       Date:  2013-04-01       Impact factor: 3.738

6.  Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.

Authors:  Young Min Kim; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Jae Myung Cha; Jung Won Jeon; Jin Young Yoon; Min Seob Kwak
Journal:  Saudi J Gastroenterol       Date:  2018 Nov-Dec       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.